NCT05183984 2026-04-13
NIRVANA-1
ARCAGY/ GINECO GROUP
Phase 2 Recruiting
Clinical Trials
23 trialsNCT05143970 2026-03-20
CHANCES
Institut Paoli-Calmettes
Phase 1 Recruiting
NCT04575935 2026-03-05
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT07033819 2026-02-27
Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT03943173 2026-02-25
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT06990503 2025-05-25
SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer
Tongji Hospital
Phase 3 Not yet recruiting
NCT05704621 2025-03-06
SOCCER-P
Korea University Guro Hospital
Phase 2 Recruiting
NCT03314740 2025-01-10
BAROCCO
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT05684731 2024-08-13
K19017-004
Tongji Hospital
Phase 1 Recruiting
NCT03539406 2024-08-09
INTRO
Radboud University Medical Center
Phase 1 Completed
NCT03755739 2024-06-25
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Phase 2/3 Recruiting
NCT05410938 2023-07-10
Intraperitoneal Chemotherapy Versus Triweekly Chemotherapy
Far Eastern Memorial Hospital
Completed
NCT04201561 2023-06-26
SELENIUM
Seoul National University Hospital
Phase 3 Unknown
NCT05607329 2022-11-07
Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial
Women's Hospital School Of Medicine Zhejiang University
Phase NA Recruiting
NCT01809379 2022-07-08
Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer
Ruhr University of Bochum
Phase 2 Completed
NCT04795596 2022-04-15
Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers
Menoufia University
Phase 2/3 Withdrawn
NCT05170594 2021-12-28
A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer
The Second Affiliated Hospital of Shandong First Medical University
Phase 2 Unknown
NCT05059782 2021-09-28
Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer
Xi'an Jiaotong University
Phase NA Unknown
NCT04747717 2021-02-11
Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer
N.N. Petrov National Medical Research Center of Oncology
Phase NA Unknown
NCT02728622 2016-04-05
Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 3 Completed
NCT00021034 2013-06-18
Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00003358 2013-01-16
Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00157560 2008-01-03
Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma
Massachusetts General Hospital
Phase 2 Completed